CRIS Current Research Information System

CHIARINI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.249
EU - Europa 1.934
AS - Asia 1.889
AF - Africa 139
SA - Sud America 104
OC - Oceania 3
Totale 6.318
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.224
IT - Italia 586
VN - Vietnam 535
SG - Singapore 528
CN - Cina 425
GB - Regno Unito 377
SE - Svezia 233
DE - Germania 219
HK - Hong Kong 153
IN - India 90
FR - Francia 86
BR - Brasile 75
RU - Federazione Russa 74
UA - Ucraina 66
IE - Irlanda 60
NL - Olanda 56
FI - Finlandia 43
TG - Togo 41
EE - Estonia 35
ZA - Sudafrica 34
CI - Costa d'Avorio 30
JP - Giappone 28
CH - Svizzera 22
BG - Bulgaria 19
JO - Giordania 18
KR - Corea 16
PH - Filippine 16
SC - Seychelles 16
BE - Belgio 15
CA - Canada 15
AR - Argentina 13
BD - Bangladesh 12
IQ - Iraq 12
ID - Indonesia 10
TR - Turchia 10
HR - Croazia 9
NG - Nigeria 9
PK - Pakistan 8
TH - Thailandia 8
PL - Polonia 6
LT - Lituania 5
MX - Messico 5
UZ - Uzbekistan 5
EC - Ecuador 4
GR - Grecia 4
CL - Cile 3
CO - Colombia 3
CZ - Repubblica Ceca 3
ES - Italia 3
SA - Arabia Saudita 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
DK - Danimarca 2
EG - Egitto 2
ET - Etiopia 2
KZ - Kazakistan 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
PY - Paraguay 2
RO - Romania 2
UY - Uruguay 2
AL - Albania 1
AT - Austria 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GI - Gibilterra 1
HN - Honduras 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
LB - Libano 1
MD - Moldavia 1
MY - Malesia 1
MZ - Mozambico 1
NP - Nepal 1
PE - Perù 1
SD - Sudan 1
SI - Slovenia 1
TN - Tunisia 1
Totale 6.318
Salva come PNG Salva come JPEG
Città #
Singapore 341
Southend 316
Ashburn 253
Parma 218
Fairfield 204
Chandler 182
Santa Clara 149
Hong Kong 147
Ho Chi Minh City 119
Dong Ket 111
San Jose 101
Ann Arbor 97
Wilmington 97
Woodbridge 96
Houston 94
Hanoi 92
Seattle 89
Bologna 85
Princeton 79
Cambridge 73
Beijing 65
Dublin 60
Boardman 55
Lomé 41
Helsinki 38
Lauterbourg 37
Nanjing 33
Jacksonville 32
Reggio Emilia 31
Westminster 31
Abidjan 30
Padova 30
Hefei 26
Los Angeles 23
Bremen 22
Berlin 21
Dallas 21
Redondo Beach 21
Sofia 19
Amman 18
Council Bluffs 18
New York 18
Saint Petersburg 18
Turin 18
Shanghai 17
Bern 16
Frankfurt am Main 16
Jinan 16
Shenyang 16
Tokyo 16
Des Moines 15
Falkenstein 15
Brussels 14
Seoul 14
São Paulo 13
Florence 12
Guangzhou 12
Milan 12
Nanchang 12
San Diego 12
Haiphong 11
Changsha 10
Tianjin 10
Abeokuta 9
Da Nang 9
Medford 9
Toronto 9
Washington 9
Hebei 8
Orem 8
Rome 8
Biên Hòa 7
Buffalo 7
Hangzhou 7
Redmond 7
Can Tho 6
Falls Church 6
London 6
Moscow 6
Mülheim 6
Ningbo 6
Olalla 6
Phoenix 6
Redwood City 6
The Dalles 6
Warsaw 6
Amsterdam 5
Baghdad 5
Haikou 5
Hải Dương 5
Jakarta 5
Lappeenranta 5
Mahé 5
Mountain View 5
Norwalk 5
San Francisco 5
Udine 5
Bến Tre 4
Durham 4
Fuzhou 4
Totale 4.158
Salva come PNG Salva come JPEG
Nome #
Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance 588
Lamin A and prelamin A counteract invasiveness of osteosarcoma cells 269
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia. 221
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. 204
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. 193
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines. 187
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 174
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 172
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 168
Lamin A acts a tumor suppressor in Ewing sarcoma promoting neural differentiation and reducing cell migration and invasion 167
A role of PI-PLCb1 in G1/S transition in human erythroleukemia k562 cells 166
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 165
Involvement of nuclear PLC{beta}1 in lamin B1 phosphorylation and G2/M cell cycle progression. 162
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. 160
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia. 158
Assessment of the structural and functional characteristics of human mesenchymal stem cells associated with a prolonged exposure of morphine 158
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage 155
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. 154
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 152
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 149
Inhibition of methyltransferase dot1l sensitizes to sorafenib treatment aml cells irrespective of mll-rearrangements: A novel therapeutic strategy for pediatric aml 144
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis 143
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells. 142
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 142
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. 139
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 137
Dual inhibition of class IA phoshatidylinositol 3-kinase and mTOR as a new therapeutic option for T-cell acute lymphoblastic leukemia. 136
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). 132
A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2) INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CELL LINES 129
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 125
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. 122
Cellular senescence in vascular wall mesenchymal stromal cells, a possible contribution to the development of aortic aneurysm 121
The emerging role of the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in normal myelopoieis and leukemogenesis. 119
The role played by Wnt/beta-catenin signaling pathway in acute lymphoblastic leukemia. 115
Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells 113
Targeting metabolic vulnerabilities and aberrant signal transduction pathways in paediatric T-cell Acute Lymphoblastic Leukaemia (T-ALL) 107
The unfolded protein response: a novel therapeutic target in acute leukemias. 99
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia 94
Targeting the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in acute myelogenous leukaemia. 83
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients 81
null 69
Surface Charge Overrides Protein Corona Formation in Determining the Cytotoxicity, Cellular Uptake, and Biodistribution of Silver Nanoparticles 24
Totale 6.438
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.434
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.434
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021194 0 0 0 0 0 0 0 0 0 22 21 151
2021/2022797 87 24 54 54 68 32 15 64 25 128 140 106
2022/2023885 79 110 45 113 67 70 32 45 152 34 87 51
2023/2024343 19 39 32 38 23 59 13 13 10 38 21 38
2024/20251.047 31 113 134 82 214 71 75 42 9 52 44 180
2025/20261.745 145 210 161 115 234 128 174 75 367 136 0 0
Totale 6.438